Actively Recruiting
Evaluating Accelerated Neuromodulation Therapy Using Intermittent Theta Burst Stimulation in Young Adults at High Risk for Psychosis
Led by Douglas Mental Health University Institute · Updated on 2026-08-28
40
Participants Needed
1
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating an accelerated form of neuromodulation therapy called intermittent theta burst stimulation iTBS to evaluate its safety, feasibility, and tolerability in young adults aged 18 to 34 who are at clinical high risk for psychosis CHR-P. This early-phase pilot study also explores whether this treatment can affect biomarkers related to treatment response and depressive symptoms, using digital tools and behavioral tasks. Participants are randomly assigned to receive either active iTBS or sham stimulation targeting the left dorsolateral prefrontal cortex over five consecutive days. The active treatment involves up to 10 sessions per day with precise pulse delivery using a MagVenture device, while the sham group receives the same treatment schedule without therapeutic stimulation. The study uses standard scalp-based targeting rather than MRI-guided methods due to its pilot nature. Throughout the study, participants complete clinical interviews, questionnaires, cognitive tests, and behavioral tasks. They wear a Fitbit and use smartphone apps for digital monitoring starting at least two weeks before treatment and continuing through follow-up visits at 1 week, 1 month, and 3 months after treatment. Researchers measure safety, treatment adherence, changes in depressive symptoms, and neurocomputational biomarkers to inform future trials.
CONDITIONS
Brief Title
Accelerated Neuromodulation Therapy and Neurocomputational Biomarkers in Individuals at Clinical High Risk for Psychosis
Research Team
A
Ashley Choucroun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here